Literature DB >> 25744048

Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.

Qing Xia1, Shuai Dong1, Ping-Da Bian2, Jue Wang2, Cheng-Jiang Li3.   

Abstract

Papillary thyroid carcinoma (PTC) is a common thyroid malignancy. Elderly patients have more severe disease and more complications following postoperative endocrine therapy to control thyroid-stimulating hormone (TSH) levels. We aimed to identify optimal postoperative serum TSH levels in elderly patients to prevent recurrence and metastasis and minimize complications. This retrospective cohort study collected data of 87 consecutive elderly patients (age >75) who underwent surgery for PTC with postoperative levothyroxine therapy (50-150 μg/d) between January 2006 and June 2008 and were followed until 2013. After 24 patients with TSH fluctuations and incomplete data were excluded, 73 patients were grouped based on postoperative TSH levels: Group A, 0.3-0.5 mIU/mL; Group B, 0.1-0.3 mIU/mL; and Group C <0.1 mIU/mL (n = 24, 25, 24, respectively). Subjects' baseline, preoperative data, postoperative complications and 1-, 3- and 5-year follow-up data were compared between groups. No significant differences in gender, age (median age of 80 years old), surgery type or clinical characteristics were found between groups (all p value >0.05). Postoperatively, all subjects had normal ECG and neck ultrasound, no osteoporosis, and no differences in survival rate or metastasis. Five-year follow-up revealed significant differences in development of arrhythmias, osteoporosis, insomnia and anxiety between Groups B (0.1-0.3 mIU/mL) and C (<0.1 mIU/mL) compared to Group A (0.3-0.5 mIU/mL). Postoperative incidence of PTC recurrence and metastasis remained stable in elderly patients undergoing thyroid surgery and endocrine therapy but complications increased significantly with increasing TSH levels. Controlling TSH to lower limits of normal may help prevent PTC recurrence and metastasis and reduce complications in this high-risk population.

Entities:  

Keywords:  Elderly; Endocrine therapy; Papillary thyroid carcinoma; Thyroid function; Thyroid surgery; Thyroid-stimulating hormone

Mesh:

Substances:

Year:  2015        PMID: 25744048     DOI: 10.1007/s00405-015-3564-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  18 in total

Review 1.  Clinical practice. Subclinical hyperthyroidism.

Authors:  A D Toft
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

Review 3.  Thyroid-hormone therapy and thyroid cancer: a reassessment.

Authors:  Bernadette Biondi; Sebastiano Filetti; Martin Schlumberger
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2005-11

4.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

Review 5.  Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 6.  Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma.

Authors:  M R Pelizzo; I Merante Boschin; A Toniato; C Pagetta; E Casal Ide; C Mian; D Rubello
Journal:  Minerva Endocrinol       Date:  2008-12       Impact factor: 2.184

7.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

8.  Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.

Authors:  E Jódar; M Begoña López; L García; D Rigopoulou; G Martínez; F Hawkins
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

9.  Is thyroid hormone suppression therapy prothrombotic?

Authors:  McDonald K Horne; Kulvinder K Singh; Kathryn G Rosenfeld; Robert Wesley; Monica C Skarulis; Paula K Merryman; Ann Cullinane; Rene Costello; Amy Patterson; Thomas Eggerman; Donna M Bernstein; Frank Pucino; Gyorgy Csako
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

10.  Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.

Authors:  C Marcocci; F Golia; G Bruno-Bossio; E Vignali; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

View more
  11 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

3.  Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival.

Authors:  Juan J Díez; Emma Anda; Victoria Alcazar; María L Isidro; Cristina Familiar; Miguel Paja; Patricia Rojas Marcos; Begoña Pérez-Corral; Elena Navarro; Ana R Romero-Lluch; Amelia Oleaga; María J Pamplona; José C Fernández-García; Ana Megía; Laura Manjón; Cecilia Sánchez-Ragnarsson; Pedro Iglesias; Julia Sastre
Journal:  Endocrine       Date:  2022-05-18       Impact factor: 3.925

Review 4.  Update on the treatment of hypothyroidism.

Authors:  Jacqueline Jonklaas
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

5.  Prognosis of papillary thyroid carcinoma in elderly patients after thyroid resection: A retrospective cohort analysis.

Authors:  Nathalie Chereau; Christophe Trésallet; Severine Noullet; Gaelle Godiris-Petit; Frederique Tissier; Laurence Leenhardt; Fabrice Menegaux
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 6.  Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.

Authors:  Narcis Tribulova; Lin Hai Kurahara; Peter Hlivak; Katsuya Hirano; Barbara Szeiffova Bacova
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

7.  CREB3 Transactivates lncRNA ZFAS1 to Promote Papillary Thyroid Carcinoma Metastasis by Modulating miR-373-3p/MMP3 Regulatory Axis.

Authors:  Gang Wang; Yuan Le; Liping Wei; Lian Cheng
Journal:  Int J Endocrinol       Date:  2021-06-21       Impact factor: 3.257

8.  Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma.

Authors:  Bin Zhou; Hailin Shan; Ying Su; Kai Xia; Runlong Zou; Qing Shao
Journal:  Oncotarget       Date:  2017-07-15

9.  MiR-145 functions as a tumor suppressor in Papillary Thyroid Cancer by inhibiting RAB5C.

Authors:  Wei Zhang; Wenyue Ji; Tianshu Li; Ting Liu; Xudong Zhao
Journal:  Int J Med Sci       Date:  2020-07-25       Impact factor: 3.738

Review 10.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.